Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Ранг среди акций #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Цена акции
$150.78
Последняя синхронизация: 2026-09-18
Рыночная капитализация
$187.20B
Изменение (1 день)
-0.08%
Изменение (1 год)
32.15%
Страна
US
Торговля Gilead Sciences, Inc. (GILD)

Категория

Прибыль Gilead Sciences, Inc. (GILD)
Прибыль на Jun 2026 TTM: $-1.96B
Согласно последним финансовым отчетам Gilead Sciences, Inc., текущая прибыль компании составляет $-1.96B. В 2024 году компания получила прибыль $690.00M, меньше, чем прибыли за 2023, которая составила $6.86B. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Gilead Sciences, Inc. с 2000 по 2026
Прибыль в конце каждого года
Год Прибыль Изменить
2026 (TTM) $-1.96B -119.96%
2025 $9.80B 1,319.71%
2024 $690.00M -89.94%
2023 $6.86B 17.97%
2022 $5.81B -29.77%
2021 $8.28B 395.99%
2020 $1.67B -67.66%
2019 $5.16B -33.84%
2018 $7.80B -42.35%
2017 $13.53B -20.87%
2016 $17.10B -21.06%
2015 $21.66B 45.79%
2014 $14.86B 253.04%
2013 $4.21B 16.50%
2012 $3.61B -1.07%
2011 $3.65B -6.71%
2010 $3.91B 11.75%
2009 $3.50B 31.03%
2008 $2.67B 17.72%
2007 $2.27B -455.74%
2006 $-638.21M -154.93%
2005 $1.16B 76.99%
2004 $656.42M -491.82%
2003 $-167.53M -328.26%
2002 $73.40M 27.76%
2001 $57.45M -237.08%
2000 $-41.91M 0.00%
Прибыль схожих компаний или конкурентов
Компания Прибыль Разница в прибыли Страна
$33.59B -1,818.38%
US
$25.20B -1,388.80%
US
$8.70B -544.96%
US
$21.39B -1,194.03%
CH
$5.95B -404.25%
US